See more : BluMetric Environmental Inc. (SEPOF) Income Statement Analysis – Financial Results
Complete financial analysis of Pliant Therapeutics, Inc. (PLRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pliant Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sourcenext Corporation (4344.T) Income Statement Analysis – Financial Results
- Ingdan, Inc. (0400.HK) Income Statement Analysis – Financial Results
- Satia Industries Limited (SATIA.NS) Income Statement Analysis – Financial Results
- ImmuCell Corporation (ICCC) Income Statement Analysis – Financial Results
- ATEX Resources Inc. (ATX.V) Income Statement Analysis – Financial Results
Pliant Therapeutics, Inc. (PLRX)
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.58M | 9.69M | 7.57M | 41.82M | 57.05M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 3.68M | 3.20M | 0.00 | 0.00 | 666.00K | 0.00 |
| Gross Profit | 1.58M | 6.00M | 4.37M | 41.82M | 57.05M | -666.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 61.99% | 57.69% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 127.80M | 96.94M | 77.55M | 66.19M | 47.35M | 24.42M | 14.53M |
| General & Administrative | 57.93M | 39.95M | 27.56M | 17.27M | 10.93M | 6.50M | 3.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 57.93M | 39.95M | 27.56M | 17.27M | 10.93M | 6.50M | 3.82M |
| Other Expenses | 0.00 | 0.00 | -77.55M | -366.00K | -216.00K | -49.00K | 0.00 |
| Operating Expenses | 185.73M | 136.89M | 27.56M | 83.46M | 58.28M | 30.92M | 18.35M |
| Cost & Expenses | 185.73M | 136.89M | 27.56M | 83.46M | 58.28M | 30.92M | 18.35M |
| Interest Income | 24.08M | 4.67M | 272.00K | 478.00K | 816.00K | 688.00K | 16.00K |
| Interest Expense | 1.27M | 791.00K | 272.00K | 366.00K | 216.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.84M | 3.68M | 3.20M | 1.31M | 1.11M | 666.00K | 292.00K |
| EBITDA | -158.23M | -118.85M | -95.73M | -40.34M | -118.00K | -30.25M | -18.06M |
| EBITDA Ratio | -10,014.43% | -1,265.15% | -263.95% | -99.59% | -0.21% | 0.00% | 0.00% |
| Operating Income | -184.15M | -127.20M | -19.99M | -41.65M | -1.23M | -30.92M | -18.35M |
| Operating Income Ratio | -11,654.75% | -1,313.37% | -263.95% | -99.59% | -2.16% | 0.00% | 0.00% |
| Total Other Income/Expenses | 22.81M | 3.88M | 272.00K | 112.00K | 600.00K | 639.00K | 16.00K |
| Income Before Tax | -161.34M | -123.32M | -19.71M | -41.53M | -631.00K | -30.28M | -18.33M |
| Income Before Tax Ratio | -10,211.14% | -1,273.32% | -260.35% | -99.32% | -1.11% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.82M | -1.81M | -1.79M | -816.00K | 639.00K | 2.29M |
| Net Income | -161.34M | -121.50M | -17.91M | -39.75M | 185.00K | -30.28M | -20.62M |
| Net Income Ratio | -10,211.14% | -1,254.50% | -236.49% | -95.05% | 0.32% | 0.00% | 0.00% |
| EPS | -2.75 | -2.89 | -0.50 | -1.12 | 0.01 | -1.83 | -25.67 |
| EPS Diluted | -2.75 | -2.89 | -0.50 | -1.12 | 0.01 | -1.83 | -25.67 |
| Weighted Avg Shares Out | 58.72M | 42.02M | 35.85M | 35.55M | 35.55M | 16.51M | 803.50K |
| Weighted Avg Shares Out (Dil) | 58.72M | 42.02M | 35.85M | 35.55M | 35.55M | 16.51M | 803.50K |
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
INTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment...
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery...
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on September 30, 2024 it granted stock options to purchase an aggregate of 120,000 shares of common stock upon vesting to Gary...
Pliant Therapeutics to Participate in Upcoming Investor Events
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the...
Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced four upcoming presentations...
Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Keith Cummings, M.D., Chief Financial Officer, and Éric Lefebvre, M.D., Chief Medical Officer, will participate in a fireside chat at the Canaccord...
7 Biotech Stocks to Buy on the Dip: June 2024
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
SOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Steve...
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on June 10, 2024, it granted stock options to purchase an aggregate of 120,000 shares of common stock upon vesting to Chohee...
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced two poster presentations,...
Source: https://incomestatements.info
Category: Stock Reports